Kenvue Inc. (NYSE:KVUE) Shares Bought by Mackenzie Financial Corp

Mackenzie Financial Corp raised its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 12.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 444,128 shares of the company's stock after buying an additional 50,279 shares during the period. Mackenzie Financial Corp's holdings in Kenvue were worth $9,482,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geneos Wealth Management Inc. acquired a new position in Kenvue during the fourth quarter valued at approximately $29,000. SRS Capital Advisors Inc. lifted its position in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after buying an additional 571 shares in the last quarter. Asset Planning Inc acquired a new position in Kenvue during the fourth quarter valued at approximately $42,000. Clarity Asset Management Inc. purchased a new stake in shares of Kenvue during the fourth quarter valued at approximately $45,000. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of Kenvue during the fourth quarter valued at approximately $46,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Up 1.2%

Shares of NYSE:KVUE traded up $0.28 during midday trading on Friday, reaching $23.86. The company had a trading volume of 30,016,864 shares, compared to its average volume of 16,346,058. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock's fifty day moving average price is $23.27 and its 200-day moving average price is $22.63. The stock has a market capitalization of $45.78 billion, a P/E ratio of 45.02, a PEG ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a one year low of $17.67 and a one year high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The firm had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same quarter in the previous year, the firm earned $0.28 earnings per share. The firm's revenue for the quarter was down 3.9% compared to the same quarter last year. Equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.44%. Kenvue's payout ratio is 149.09%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on KVUE shares. Canaccord Genuity Group lifted their price objective on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Evercore ISI started coverage on shares of Kenvue in a research note on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective on the stock. Royal Bank of Canada reiterated a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Citigroup lifted their price objective on shares of Kenvue from $22.00 to $24.50 and gave the company a "neutral" rating in a research note on Friday, May 9th. Finally, Piper Sandler lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.